Enanta Pharmaceuticals Inc (ENTA) Holdings Increased by Bridgeway Capital Management Inc.

Bridgeway Capital Management Inc. raised its position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 11.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 26,600 shares of the biotechnology company’s stock after acquiring an additional 2,800 shares during the period. Bridgeway Capital Management Inc.’s holdings in Enanta Pharmaceuticals were worth $2,273,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ENTA. Principal Financial Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 3.2% in the first quarter. Principal Financial Group Inc. now owns 113,524 shares of the biotechnology company’s stock worth $9,185,000 after acquiring an additional 3,565 shares during the last quarter. Xact Kapitalforvaltning AB acquired a new position in shares of Enanta Pharmaceuticals in the second quarter worth $290,000. Amalgamated Bank acquired a new position in shares of Enanta Pharmaceuticals in the second quarter worth $315,000. Dupont Capital Management Corp increased its stake in shares of Enanta Pharmaceuticals by 85.4% in the second quarter. Dupont Capital Management Corp now owns 12,303 shares of the biotechnology company’s stock worth $1,426,000 after acquiring an additional 5,668 shares during the last quarter. Finally, TD Asset Management Inc. increased its stake in shares of Enanta Pharmaceuticals by 203.2% in the second quarter. TD Asset Management Inc. now owns 40,761 shares of the biotechnology company’s stock worth $4,724,000 after acquiring an additional 27,319 shares during the last quarter. 85.18% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ ENTA opened at $82.12 on Tuesday. Enanta Pharmaceuticals Inc has a 1-year low of $47.01 and a 1-year high of $127.77. The firm has a market capitalization of $1.53 billion, a PE ratio of 21.62 and a beta of 0.91.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, November 26th. The biotechnology company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.06. The business had revenue of $67.20 million for the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a net margin of 34.82% and a return on equity of 21.56%. Enanta Pharmaceuticals’s revenue for the quarter was down 11.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.86 earnings per share. Research analysts predict that Enanta Pharmaceuticals Inc will post 1.7 EPS for the current fiscal year.

A number of equities analysts have recently weighed in on the stock. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, November 20th. Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, November 27th. TheStreet downgraded shares of Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, November 26th. Finally, Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Enanta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $104.00.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,155 shares of the stock in a transaction on Thursday, September 20th. The shares were sold at an average price of $95.32, for a total transaction of $396,054.60. Following the transaction, the vice president now directly owns 4,155 shares of the company’s stock, valued at $396,054.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tim Ocain sold 25,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $83.64, for a total transaction of $2,091,000.00. The disclosure for this sale can be found here. Corporate insiders own 10.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2018/12/04/enanta-pharmaceuticals-inc-enta-holdings-increased-by-bridgeway-capital-management-inc.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

See Also: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit